StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Collaboration by Year

Collaboration — Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) ($M) ($M)

Merck Collaboration: $375M in FY2025, up 4.7% from a year earlier.

Latest, FY2025
375
Period ended Dec 31, 2025
Change on a year earlier
+4.7%
358 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-24) ↗

Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCollaboration — Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) ($M) ($M)Year on yearSource
FY2025Dec 31, 2025375+4.7%Form 10-K (filed 2026-02-24) ↗
FY2024Dec 31, 2024358+64.2%Form 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 2023218-24.3%Form 10-K (filed 2026-02-24) ↗
FY2022Dec 31, 2022288–Form 10-K (filed 2025-02-25) ↗

Breakdown

What makes up collaboration

Cite this data

StockData. (2026). Merck Collaboration ($M), annual FY2022–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-moderna

See every metric in the Merck KPI table. Data updated Oct 26, 2026.